Investing.comCodex · 实盘不做把握 3/10
北京时间·🕒 发布 20:32:44时区推断·⟳ 抓取 20:33:17·⚡ 决策 08-04 22:25:02 +1h51m·83.9 天前
Entera Bio的EB613二期事后分析获ASBMR大会海报展示
EB613的161例二期事后分析获ASBMR Plenary Poster展示，并计划约750例三期试验，但本次不是新临床疗效读出或监管批准。
📄 原文Investing.com↗ 原文
Entera Bio’s EB613 data selected for plenary poster at ASBMR
BofA says this memory stock could double. Here are 5 reasons why TEL AVIV - Entera Bio Ltd. (NASDAQ:ENTX) announced tha…
不做 Entera Bio（ENTX.US）
与同批r05为同一EB613会议展示催化的转述，且仅为学术海报入选，不是新疗效/监管/融资事件，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-04 · 扩散 low · price-in 风险 medium ↗
关键理由
- EB613的161例二期事后分析获ASBMR Plenary Poster展示，并计划约750例三期试验，但本次不是新临床疗效读出或监管批准。
主要风险
- 会议海报入选通常是学术曝光，不直接改变药物成功概率、商业化时间表或现金流。
原文全文
展开原文 · 1,966 字
BofA says this memory stock could double. Here are 5 reasons why
TEL AVIV - Entera Bio Ltd. (NASDAQ:ENTX) announced that post-hoc data from its Phase 2 clinical trial of EB613, an oral PTH(1-34) tablet, has been selected for two presentations at the American Society for Bone and Mineral Research 2026 Annual Meeting, according to a press release statement.
The presentations will take place October 9-12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston. One presentation has been designated as a Plenary Poster Presentation, a category selected by the ASBMR program committee for highly ranked poster presentations.
EB613 is being developed as an oral tablet treatment for osteoporosis. The Phase 2 study randomized 161 postmenopausal women with low bone mass or osteoporosis to placebo or four EB613 dose levels for six months.
The company is planning a Phase 3 trial of EB613 involving approximately 750 postmenopausal women with osteoporosis to support a potential New Drug Application submission for treatment of postmenopausal osteoporosis.
The post-hoc analysis evaluated the relationship between baseline T-score severity and EB613 effects on Bone Mineral Density and Bone Turnover Markers at six months in postmenopausal women with osteoporosis.
The abstract titled "EB613, Oral PTH(1-34) Tablet, Shows Markedly Enhanced Anabolic Effects in Postmenopausal Women with Osteoporosis at High Risk of Fracture: Insights from Phase 2 Trial" will be presented during the Welcome Reception and Plenary Poster Session on Friday, October 9, 2026, from 5:30-7:00 p.m. ET, and again during Poster Session II on Sunday, October 11, 2026, from 2:00-3:30 p.m. ET.
The company completed a Phase 2, six-month, 161-patient, placebo-controlled study that met biomarker and BMD endpoints in women with postmenopausal osteoporosis or low BMD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
TEL AVIV - Entera Bio Ltd. (NASDAQ:ENTX) announced that post-hoc data from its Phase 2 clinical trial of EB613, an oral PTH(1-34) tablet, has been selected for two presentations at the American Society for Bone and Mineral Research 2026 Annual Meeting, according to a press release statement.
The presentations will take place October 9-12, 2026, at the John B. Hynes Veterans Memorial Convention Center in Boston. One presentation has been designated as a Plenary Poster Presentation, a category selected by the ASBMR program committee for highly ranked poster presentations.
EB613 is being developed as an oral tablet treatment for osteoporosis. The Phase 2 study randomized 161 postmenopausal women with low bone mass or osteoporosis to placebo or four EB613 dose levels for six months.
The company is planning a Phase 3 trial of EB613 involving approximately 750 postmenopausal women with osteoporosis to support a potential New Drug Application submission for treatment of postmenopausal osteoporosis.
The post-hoc analysis evaluated the relationship between baseline T-score severity and EB613 effects on Bone Mineral Density and Bone Turnover Markers at six months in postmenopausal women with osteoporosis.
The abstract titled "EB613, Oral PTH(1-34) Tablet, Shows Markedly Enhanced Anabolic Effects in Postmenopausal Women with Osteoporosis at High Risk of Fracture: Insights from Phase 2 Trial" will be presented during the Welcome Reception and Plenary Poster Session on Friday, October 9, 2026, from 5:30-7:00 p.m. ET, and again during Poster Session II on Sunday, October 11, 2026, from 2:00-3:30 p.m. ET.
The company completed a Phase 2, six-month, 161-patient, placebo-controlled study that met biomarker and BMD endpoints in women with postmenopausal osteoporosis or low BMD.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。